Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina
- Autores
- Córdoba, Susana; Isla, Maria G; Szusz, Wanda; Vivot, Walter; Altamirano, Rodrigo; Davel, Graciela Odelsia
- Año de publicación
- 2016
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Fil: Córdoba, Susana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Fil: Isla, Maria G. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Fil: Szusz, Wanda. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Fil: Vivot, Walter. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Fil: Altamirano, Rodrigo. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina. Cátedra de Cálculo Estadístico y Biometría, Facultad de Ciencias Agrarias y Forestales, Buenos Aires; Argentina.
Fil: Davel, Graciela. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Epidemiological cut-off values (ECVs) based on minimal inhibitory concentration (MIC) distribution have been recently proposed for some antifungal drug/Cryptococcus neoformans combinations. However, these ECVs vary according to the species studied, being serotypes and the geographical origin of strains, variables to be considered. The aims were to define the wild-type (WT) population of the C. neoformans species complex (C. neoformans) isolated from patients living in Argentina, and to propose ECVs for six antifungal drugs. A total of 707 unique C. neoformans isolates obtained from HIV patients suffering cryptococcal meningitis were studied. The MIC of amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole was determined according to the EDef 7.2 (EUCAST) reference document. The MIC distribution, MIC50 , MIC90 and ECV for each of these drugs were calculated. The highest ECV, which included ≥95% of the WT population modelled, was observed for flucytosine and fluconazole (32 μg ml(-1) each). For amphotericin B, itraconazole, voriconazole and posaconazole, the ECVs were: 0.5, 0.5, 0.5 and 0.06 μg ml(-1) respectively. The ECVs determined in this study may aid in identifying the C. neoformans strains circulating in Argentina with decreased susceptibility to the antifungal drugs tested. - Fuente
- Mycoses 2016; 59(6):351-6.
- Materia
-
Argentina
Cryptococcus neoformans
VIH - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- none
- Repositorio

- Institución
- Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
- OAI Identificador
- oai:sgc.anlis.gob.ar:Publications/123456789/2106
Ver los metadatos del registro completo
| id |
SGCANLIS_cf1a4dc485cea75b7b0c76e0d232d32f |
|---|---|
| oai_identifier_str |
oai:sgc.anlis.gob.ar:Publications/123456789/2106 |
| network_acronym_str |
SGCANLIS |
| repository_id_str |
a |
| network_name_str |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN |
| spelling |
Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from ArgentinaCórdoba, SusanaIsla, Maria GSzusz, WandaVivot, WalterAltamirano, RodrigoDavel, Graciela OdelsiaArgentinaCryptococcus neoformansVIHFil: Córdoba, Susana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Isla, Maria G. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Szusz, Wanda. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Vivot, Walter. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Altamirano, Rodrigo. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina. Cátedra de Cálculo Estadístico y Biometría, Facultad de Ciencias Agrarias y Forestales, Buenos Aires; Argentina.Fil: Davel, Graciela. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Epidemiological cut-off values (ECVs) based on minimal inhibitory concentration (MIC) distribution have been recently proposed for some antifungal drug/Cryptococcus neoformans combinations. However, these ECVs vary according to the species studied, being serotypes and the geographical origin of strains, variables to be considered. The aims were to define the wild-type (WT) population of the C. neoformans species complex (C. neoformans) isolated from patients living in Argentina, and to propose ECVs for six antifungal drugs. A total of 707 unique C. neoformans isolates obtained from HIV patients suffering cryptococcal meningitis were studied. The MIC of amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole was determined according to the EDef 7.2 (EUCAST) reference document. The MIC distribution, MIC50 , MIC90 and ECV for each of these drugs were calculated. The highest ECV, which included ≥95% of the WT population modelled, was observed for flucytosine and fluconazole (32 μg ml(-1) each). For amphotericin B, itraconazole, voriconazole and posaconazole, the ECVs were: 0.5, 0.5, 0.5 and 0.06 μg ml(-1) respectively. The ECVs determined in this study may aid in identifying the C. neoformans strains circulating in Argentina with decreased susceptibility to the antifungal drugs tested.Wiley2016-06info:ar-repo/semantics/articuloinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdf1439-0507https://onlinelibrary.wiley.com/doi/abs/10.1111/myc.12479http://sgc.anlis.gob.ar/handle/123456789/210610.1111/myc.12479Mycoses 2016; 59(6):351-6.reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁNinstname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"instacron:ANLISMycosesnoneinfo:eu-repo/semantics/openAccesseng2025-11-06T10:11:01Zoai:sgc.anlis.gob.ar:Publications/123456789/2106Institucionalhttp://sgc.anlis.gob.ar/Organismo científico-tecnológicoNo correspondehttp://sgc.anlis.gob.ar/oai/biblioteca@anlis.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:a2025-11-06 10:11:01.977Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"false |
| dc.title.none.fl_str_mv |
Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina |
| title |
Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina |
| spellingShingle |
Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina Córdoba, Susana Argentina Cryptococcus neoformans VIH |
| title_short |
Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina |
| title_full |
Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina |
| title_fullStr |
Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina |
| title_full_unstemmed |
Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina |
| title_sort |
Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina |
| dc.creator.none.fl_str_mv |
Córdoba, Susana Isla, Maria G Szusz, Wanda Vivot, Walter Altamirano, Rodrigo Davel, Graciela Odelsia |
| author |
Córdoba, Susana |
| author_facet |
Córdoba, Susana Isla, Maria G Szusz, Wanda Vivot, Walter Altamirano, Rodrigo Davel, Graciela Odelsia |
| author_role |
author |
| author2 |
Isla, Maria G Szusz, Wanda Vivot, Walter Altamirano, Rodrigo Davel, Graciela Odelsia |
| author2_role |
author author author author author |
| dc.subject.none.fl_str_mv |
Argentina Cryptococcus neoformans VIH |
| topic |
Argentina Cryptococcus neoformans VIH |
| dc.description.none.fl_txt_mv |
Fil: Córdoba, Susana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina. Fil: Isla, Maria G. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina. Fil: Szusz, Wanda. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina. Fil: Vivot, Walter. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina. Fil: Altamirano, Rodrigo. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina. Cátedra de Cálculo Estadístico y Biometría, Facultad de Ciencias Agrarias y Forestales, Buenos Aires; Argentina. Fil: Davel, Graciela. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina. Epidemiological cut-off values (ECVs) based on minimal inhibitory concentration (MIC) distribution have been recently proposed for some antifungal drug/Cryptococcus neoformans combinations. However, these ECVs vary according to the species studied, being serotypes and the geographical origin of strains, variables to be considered. The aims were to define the wild-type (WT) population of the C. neoformans species complex (C. neoformans) isolated from patients living in Argentina, and to propose ECVs for six antifungal drugs. A total of 707 unique C. neoformans isolates obtained from HIV patients suffering cryptococcal meningitis were studied. The MIC of amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole was determined according to the EDef 7.2 (EUCAST) reference document. The MIC distribution, MIC50 , MIC90 and ECV for each of these drugs were calculated. The highest ECV, which included ≥95% of the WT population modelled, was observed for flucytosine and fluconazole (32 μg ml(-1) each). For amphotericin B, itraconazole, voriconazole and posaconazole, the ECVs were: 0.5, 0.5, 0.5 and 0.06 μg ml(-1) respectively. The ECVs determined in this study may aid in identifying the C. neoformans strains circulating in Argentina with decreased susceptibility to the antifungal drugs tested. |
| description |
Fil: Córdoba, Susana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina. |
| publishDate |
2016 |
| dc.date.none.fl_str_mv |
2016-06 |
| dc.type.none.fl_str_mv |
info:ar-repo/semantics/articulo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
1439-0507 https://onlinelibrary.wiley.com/doi/abs/10.1111/myc.12479 http://sgc.anlis.gob.ar/handle/123456789/2106 10.1111/myc.12479 |
| identifier_str_mv |
1439-0507 10.1111/myc.12479 |
| url |
https://onlinelibrary.wiley.com/doi/abs/10.1111/myc.12479 http://sgc.anlis.gob.ar/handle/123456789/2106 |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
Mycoses |
| dc.rights.none.fl_str_mv |
none info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
none |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Wiley |
| publisher.none.fl_str_mv |
Wiley |
| dc.source.none.fl_str_mv |
Mycoses 2016; 59(6):351-6. reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁN instname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán" instacron:ANLIS |
| reponame_str |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN |
| collection |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN |
| instname_str |
Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán" |
| instacron_str |
ANLIS |
| institution |
ANLIS |
| repository.name.fl_str_mv |
Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán" |
| repository.mail.fl_str_mv |
biblioteca@anlis.gov.ar |
| _version_ |
1848048320970227712 |
| score |
12.576249 |